Pelvic lymphadenectomy for prostate and bladder cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pelvic lymph node dissection (PLND) is an integral part of radical urologic surgery for pelvic malignancies. For many years PLND was part and parcel of radical retropubic prostatectomy for prostate cancer, though recent guidelines recommend performing PLND in conjunction with radical prostatectomy only when the nomogram-predicted risk of lymph nodes being involved with metastatic prostate cancer is greater than 2-2.5 %. This is not only because there is significant potential morbidity to PLND, but also because the therapeutic benefit of dissections in such cases is quite limited. A standard PLND is nevertheless recommended for all intermediate-risk men, and an extended PLND is recommended for high-risk men. The greatest predictor of lymph node involvement may well be the percentage of cores that are found positive on initial prostate biopsy (number of positive cores/total number of cores taken). It is recommended that one of several nomograms be used to define this risk in individual cases before deciding on whether or not to perform PLND and to what extent. While the therapeutic benefit of PLND is controversial, it is clear that men with small volume nodal disease (typically, one or two positive nodes) can be cured by removing these nodes alone and without adjuvant therapy. Strong consideration should be given to androgen deprivation therapy for most men found to have positive nodes however, particularly with several positive nodes, or lymph node density of 15 % or greater. PLND as part of a radical cystectomy for bladder cancer remains a nonnegotiable part of this operation. It appears that there is no patient who should not receive PLND during radical cystectomy, as positive lymph node rates are high in essentially all published series. An extended template PLND, superiorly to the uretero-iliac junction, is recommended for all radical cystectomy patients. High lymph node yields and a low positive lymph node density (

Original languageEnglish (US)
Title of host publicationPelvic Cancer Surgery: Modern Breakthroughs and Future Advances
PublisherSpringer-Verlag London Ltd
Pages69-78
Number of pages10
ISBN (Print)9781447142584, 9781447142577
DOIs
StatePublished - Jan 1 2015

Fingerprint

Lymph Node Excision
Urinary Bladder Neoplasms
Prostatic Neoplasms
Lymph Nodes
Cystectomy
Nomograms
Prostatectomy
Therapeutics
Androgens
Dissection
Prostate
Guidelines
Morbidity
Biopsy

Keywords

  • Bladder cancer
  • Complications
  • Pelvic lymphadenectomy
  • Prostate cancer
  • Radical cystectomy
  • Radical prostatectomy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pavlovich, C., Gorin, M., Pierorazio, P. M., & Mullins, J. K. (2015). Pelvic lymphadenectomy for prostate and bladder cancer. In Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances (pp. 69-78). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4258-4_8

Pelvic lymphadenectomy for prostate and bladder cancer. / Pavlovich, Christian; Gorin, Michael; Pierorazio, Phillip Martin; Mullins, Jeffrey K.

Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Springer-Verlag London Ltd, 2015. p. 69-78.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pavlovich, C, Gorin, M, Pierorazio, PM & Mullins, JK 2015, Pelvic lymphadenectomy for prostate and bladder cancer. in Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Springer-Verlag London Ltd, pp. 69-78. https://doi.org/10.1007/978-1-4471-4258-4_8
Pavlovich C, Gorin M, Pierorazio PM, Mullins JK. Pelvic lymphadenectomy for prostate and bladder cancer. In Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Springer-Verlag London Ltd. 2015. p. 69-78 https://doi.org/10.1007/978-1-4471-4258-4_8
Pavlovich, Christian ; Gorin, Michael ; Pierorazio, Phillip Martin ; Mullins, Jeffrey K. / Pelvic lymphadenectomy for prostate and bladder cancer. Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Springer-Verlag London Ltd, 2015. pp. 69-78
@inbook{99f88af2755546cd8ce113f728965a3a,
title = "Pelvic lymphadenectomy for prostate and bladder cancer",
abstract = "Pelvic lymph node dissection (PLND) is an integral part of radical urologic surgery for pelvic malignancies. For many years PLND was part and parcel of radical retropubic prostatectomy for prostate cancer, though recent guidelines recommend performing PLND in conjunction with radical prostatectomy only when the nomogram-predicted risk of lymph nodes being involved with metastatic prostate cancer is greater than 2-2.5 {\%}. This is not only because there is significant potential morbidity to PLND, but also because the therapeutic benefit of dissections in such cases is quite limited. A standard PLND is nevertheless recommended for all intermediate-risk men, and an extended PLND is recommended for high-risk men. The greatest predictor of lymph node involvement may well be the percentage of cores that are found positive on initial prostate biopsy (number of positive cores/total number of cores taken). It is recommended that one of several nomograms be used to define this risk in individual cases before deciding on whether or not to perform PLND and to what extent. While the therapeutic benefit of PLND is controversial, it is clear that men with small volume nodal disease (typically, one or two positive nodes) can be cured by removing these nodes alone and without adjuvant therapy. Strong consideration should be given to androgen deprivation therapy for most men found to have positive nodes however, particularly with several positive nodes, or lymph node density of 15 {\%} or greater. PLND as part of a radical cystectomy for bladder cancer remains a nonnegotiable part of this operation. It appears that there is no patient who should not receive PLND during radical cystectomy, as positive lymph node rates are high in essentially all published series. An extended template PLND, superiorly to the uretero-iliac junction, is recommended for all radical cystectomy patients. High lymph node yields and a low positive lymph node density (",
keywords = "Bladder cancer, Complications, Pelvic lymphadenectomy, Prostate cancer, Radical cystectomy, Radical prostatectomy",
author = "Christian Pavlovich and Michael Gorin and Pierorazio, {Phillip Martin} and Mullins, {Jeffrey K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4258-4_8",
language = "English (US)",
isbn = "9781447142584",
pages = "69--78",
booktitle = "Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Pelvic lymphadenectomy for prostate and bladder cancer

AU - Pavlovich, Christian

AU - Gorin, Michael

AU - Pierorazio, Phillip Martin

AU - Mullins, Jeffrey K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pelvic lymph node dissection (PLND) is an integral part of radical urologic surgery for pelvic malignancies. For many years PLND was part and parcel of radical retropubic prostatectomy for prostate cancer, though recent guidelines recommend performing PLND in conjunction with radical prostatectomy only when the nomogram-predicted risk of lymph nodes being involved with metastatic prostate cancer is greater than 2-2.5 %. This is not only because there is significant potential morbidity to PLND, but also because the therapeutic benefit of dissections in such cases is quite limited. A standard PLND is nevertheless recommended for all intermediate-risk men, and an extended PLND is recommended for high-risk men. The greatest predictor of lymph node involvement may well be the percentage of cores that are found positive on initial prostate biopsy (number of positive cores/total number of cores taken). It is recommended that one of several nomograms be used to define this risk in individual cases before deciding on whether or not to perform PLND and to what extent. While the therapeutic benefit of PLND is controversial, it is clear that men with small volume nodal disease (typically, one or two positive nodes) can be cured by removing these nodes alone and without adjuvant therapy. Strong consideration should be given to androgen deprivation therapy for most men found to have positive nodes however, particularly with several positive nodes, or lymph node density of 15 % or greater. PLND as part of a radical cystectomy for bladder cancer remains a nonnegotiable part of this operation. It appears that there is no patient who should not receive PLND during radical cystectomy, as positive lymph node rates are high in essentially all published series. An extended template PLND, superiorly to the uretero-iliac junction, is recommended for all radical cystectomy patients. High lymph node yields and a low positive lymph node density (

AB - Pelvic lymph node dissection (PLND) is an integral part of radical urologic surgery for pelvic malignancies. For many years PLND was part and parcel of radical retropubic prostatectomy for prostate cancer, though recent guidelines recommend performing PLND in conjunction with radical prostatectomy only when the nomogram-predicted risk of lymph nodes being involved with metastatic prostate cancer is greater than 2-2.5 %. This is not only because there is significant potential morbidity to PLND, but also because the therapeutic benefit of dissections in such cases is quite limited. A standard PLND is nevertheless recommended for all intermediate-risk men, and an extended PLND is recommended for high-risk men. The greatest predictor of lymph node involvement may well be the percentage of cores that are found positive on initial prostate biopsy (number of positive cores/total number of cores taken). It is recommended that one of several nomograms be used to define this risk in individual cases before deciding on whether or not to perform PLND and to what extent. While the therapeutic benefit of PLND is controversial, it is clear that men with small volume nodal disease (typically, one or two positive nodes) can be cured by removing these nodes alone and without adjuvant therapy. Strong consideration should be given to androgen deprivation therapy for most men found to have positive nodes however, particularly with several positive nodes, or lymph node density of 15 % or greater. PLND as part of a radical cystectomy for bladder cancer remains a nonnegotiable part of this operation. It appears that there is no patient who should not receive PLND during radical cystectomy, as positive lymph node rates are high in essentially all published series. An extended template PLND, superiorly to the uretero-iliac junction, is recommended for all radical cystectomy patients. High lymph node yields and a low positive lymph node density (

KW - Bladder cancer

KW - Complications

KW - Pelvic lymphadenectomy

KW - Prostate cancer

KW - Radical cystectomy

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84947433056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947433056&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4258-4_8

DO - 10.1007/978-1-4471-4258-4_8

M3 - Chapter

SN - 9781447142584

SN - 9781447142577

SP - 69

EP - 78

BT - Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances

PB - Springer-Verlag London Ltd

ER -